Bernstein Sticks to Their Buy Rating for Molina Healthcare (MOH)

In a report released on January 16, Lance Wilkes from Bernstein maintained a Buy rating on Molina Healthcare, with a price target of $224.00. The company’s shares closed last Friday at $191.40.

Claim 50% Off TipRanks Premium

• Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
• Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

According to TipRanks, Wilkes is a 2-star analyst with an average return of 0.8% and a 50.00% success rate. Wilkes covers the Healthcare sector, focusing on stocks such as UnitedHealth, CVS Health, and Agilon Health.

Molina Healthcare has an analyst consensus of Hold, with a price target consensus of $183.64, which is a -4.05% downside from current levels. In a report released today, TipRanks – OpenAI also upgraded the stock to a Buy with a $211.00 price target.

Based on Molina Healthcare’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $11.48 billion and a net profit of $79 million. In comparison, last year the company earned a revenue of $10.34 billion and had a net profit of $326 million

Based on the recent corporate insider activity of 64 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of MOH in relation to earlier this year. Most recently, in November 2025, Schapiro Richard, a Director at MOH sold 357.00 shares for a total of $51,058.14.